Astellas Pharma FY16 Financial Results 2017

Astellas Pharma FY16 financial results presented on March 1, 2017, including discussion of Phase 1/2 clinical trial data (ATB200-02) investigating ATB200/AT2221 and progress on Galafold commercialization. The presentation includes forward-looking statements regarding preclinical and clinical development timelines, regulatory approval prospects, and projected cash position.